Loading
A phase 2 trial of Durvalumab, Tremelimumab, Lenvatinib in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT07081633 by AstraZeneca, with 114 participants enrolled, started 2025-08-05 and due to reach its primary completion in 2026-11-30. Interventions recorded: Durvalumab, Tremelimumab, Lenvatinib. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tremelimumab, Advanced hepatocellular carcinoma (BCLC C), Durvalumab, AstraZeneca.
Shares Tremelimumab, Advanced hepatocellular carcinoma (BCLC C), Durvalumab, AstraZeneca.
Shares Tremelimumab, Advanced hepatocellular carcinoma (BCLC C), Durvalumab, Anti-angiogenic therapy.
Shares Tremelimumab, Advanced hepatocellular carcinoma (BCLC C), Anti-angiogenic therapy, AstraZeneca.
Shares Advanced hepatocellular carcinoma (BCLC C), Lenvatinib, Anti-angiogenic therapy, Hepatocellular carcinoma.
Shares Durvalumab, Anti-angiogenic therapy, AstraZeneca, Hepatocellular carcinoma.
Shares Tremelimumab, Durvalumab, AstraZeneca, Immune checkpoint inhibitors.
Shares Advanced hepatocellular carcinoma (BCLC C), Lenvatinib, Anti-angiogenic therapy, Hepatocellular carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/